Kállai Judit

1.

Kállai, J., Gindele, R., Pénzes-Daku, K., Balogh, G., Kissné Bogáti, R., Bécsi, B., Katona, É., Oláh, Z., Ilonczai, P., Boda, Z., Róna-Tas, Á., Nemes, L., Marton, I., Bereczky, Z.: Clinical and Molecular Characterization of Nine Novel Antithrombin Mutations.
Int. J. Mol. Sci. 25 (5), 1-19, (article identifier: 2893), 2024.

doi DEA WoS Scopus

Journal metrics:

Q2 Catalysis

Q1 Computer Science Applications

Q1 Inorganic Chemistry

Q1 Medicine (miscellaneous)

Q2 Molecular Biology

D1 Organic Chemistry

Q1 Physical and Theoretical Chemistry

D1 Spectroscopy

2.

Béke, G., Lendvai, A., Hollósi, E., Braun, N., Theek, C., Kállai, J., Lányi, Á., Becker, M., Völker, J. M., Schulze zur Wiesche, E., Bácsi, A., Bíró, T., Mihály, J.: Topically Applied N,N-Dimethylglycine Sodium Salt Enhances Human Skin Blood Flow by Inducing Endothelial Nitric Oxide Release.
J. Invest. Dermatol. 144 (12), 2823-2827, 2024.

doi DEA WoS Scopus

Journal metrics:

Q1 Biochemistry

Q1 Cell Biology

D1 Dermatology

Q1 Molecular Biology

3.

Lendvai, A., Béke, G., Hollósi, E., Braun, N., Theek, C., Kállai, J., Lányi, Á., Becker, M., Völker, J. M., Schulze zur Wiesche, E., Bácsi, A., Bíró, T., Mihály, J.: Topically Applied N,N-Dimethylglycine Sodium Salt Enhanceshuman Skin Microcirculation By Inducing Endothelial Nitric Oxide Release.
Immunol. Szemle. 16 (3), 28-29, 2024.

DEA

4.

Szántó, G. T., Fehér, Á., Korpos, É., Gyöngyösi, A., Kállai, J., Mészáros, B., Óvári, K., Lányi, Á., Panyi, G., Varga, Z.: 5-Chloro-2-Guanidinobenzimidazole (ClGBI) Is a Non-Selective Inhibitor of the Human HV1 Channel.
Pharmaceuticals (Basel). 16 (5), 1-15, (article identifier: 656), 2023.

doi DEA WoS Scopus

Journal metrics:

Q2 Drug Discovery

Q2 Molecular Medicine

Q1 Pharmaceutical Science

5.

Szegedi, K., Szabó, Z., Kállai, J., Király, J., Szabó, E., Bereczky, Z., Juhász, É., Dezső, B., Szász, C., Zsebik, B., Flaskó, T., Halmos, G.: Potential Role of VHL, PTEN, and BAP1 Mutations in Renal Tumors.
J Clin Med. 12 (13), 1-18, (article identifier: 4538), 2023.

doi DEA WoS Scopus

Journal metrics:

Q1 Medicine (miscellaneous)

6.

Cozzolino, M., Gyöngyösi, A., Korpos, É., Gogolák, P., Naseem, M. U., Kállai, J., Lányi, Á., Panyi, G.: The Voltage-Gated Hv1 H<U+009a> Channel Is Expressed in Tumor-Infiltrating Myeloid-Derived Suppressor Cells.
Int. J. Mol. Sci. 24 (7), 1-24, (article identifier: 6216), 2023.

doi DEA WoS Scopus

Journal metrics:

Q2 Catalysis

Q1 Computer Science Applications

D1 Inorganic Chemistry

Q1 Medicine (miscellaneous)

Q2 Molecular Biology

D1 Organic Chemistry

Q1 Physical and Theoretical Chemistry

D1 Spectroscopy

7.

Erdős, M., Mironska, K., Kareva, L., Stavrik, K., Hasani, A., Lányi, Á., Kállai, J., Maródi, L.: A novel mutation in identified in a patient with autosomal recessive agammaglobulinemia: the impact of the J-Project.
Pediatr. Allergy Immunol. 33 (6), 1-7, (article identifier: 13805), 2022.

doi DEA WoS Scopus

Journal metrics:

Q2 Immunology

Q2 Immunology and Allergy

Q1 Pediatrics, Perinatology and Child Health

8.

Baráth, B., Kissné Bogáti, R., Miklós, T., Kállai, J., Mezei, Z. A., Bereczky, Z., Muszbek, L., Katona, É.: Effect of [alfa]2-plasmin inhibitor heterogeneity on the risk of venous thromboembolism.
Thromb. Res. 203, 110-116, 2021.

doi DEA WoS Scopus

Journal metrics:

Q1 Hematology

9.

Gindele, R., Pénzes-Daku, K., Balogh, G., Kállai, J., Kissné Bogáti, R., Bécsi, B., Erdődi, F., Katona, É., Bereczky, Z.: Investigation of the Differences in Antithrombin to Heparin Binding among Antithrombin Budapest 3, Basel, and Padua Mutations by Biochemical and In Silico Methods.
Biomolecules. 11 (4), 1-18, (article identifier: 544), 2021.

doi DEA WoS Scopus

Journal metrics:

Q2 Biochemistry

Q2 Molecular Biology

10.

Erdős, M., Tsumura, M., Kállai, J., Lányi, Á., Nyúl, Z., Balázs, G., Okada, S., Maródi, L.: Novel STAT-3 gain-of-function variant with hypogammaglobulinemia and recurrent infection phenotype.
Clin. Exp. Immunol. 205 (3), 354-362, 2021.

doi DEA

Journal metrics:

Q2 Immunology

Q2 Immunology and Allergy

11.

Gindele, R., Kerényi, A., Kállai, J., Pfliegler, G., Schlammadinger, Á., Szegedi, I., Major, T., Szabó, Z., Bagoly, Z., Kiss, C., Kappelmayer, J., Bereczky, Z.: Resolving Differential Diagnostic Problems in von Willebrand Disease, in Fibrinogen Disorders, in Prekallikrein Deficiency and in Hereditary Hemorrhagic Telangiectasia by Next-Generation Sequencing.
Life (Basel). 11 (3), 1-23, (article identifier: 202), 2021.

doi DEA

Journal metrics:

Q2 Biochemistry, Genetics and Molecular Biology (miscellaneous)

Q2 Ecology, Evolution, Behavior and Systematics

Q2 Paleontology

Q3 Space and Planetary Science

12.

Balogh, L., Katona, É., Mezei, Z. A., Kállai, J., Gindele, R., Édes, I., Muszbek, L., Papp, Z., Bereczky, Z.: Effect of factor XIII levels and polymorphisms on the risk of myocardial infarction in young patients.
Mol. Cell. Biochem. 448 (1-2), 199-209, 2018.

doi DEA

Journal metrics:

Q3 Cell Biology

Q2 Clinical Biochemistry

Q1 Medicine (miscellaneous)

Q3 Molecular Biology

13.

Mezei, Z. A., Katona, É., Kállai, J., Bereczky, Z., Somodi, L., Molnár, É., Kovács, B., Miklós, T., Ajzner, É., Muszbek, L.: Factor XIII levels and factor XIII B subunit polymorphisms in patients with venous thromboembolism.
Thromb. Res. 158, 93-97, 2017.

DEA WoS Scopus

Journal metrics:

Q2 Hematology

14.

Bereczky, Z., Gindele, R., Speker, M., Kállai, J.: Deficiencies of the natural anticoagulants: novel clinical laboratory aspects of thrombophilia testing.
EJIFCC. 27 (2), 130-146, 2016.

DEA

15.

Mezei, Z. A., Katona, É., Kállai, J., Bereczky, Z., Molnár, É., Kovács, B., Ajzner, É., Bagoly, Z., Miklós, T., Muszbek, L.: Regulation of plasma factor XIII levels in healthy individuals; a major impact by subunit B intron K c.1952+144 C>G polymorphism.
Thromb. Res. 148, 101-106, 2016.

doi DEA WoS Scopus

Journal metrics:

Q2 Hematology

Publication list